Sign in
CING Stock Price, Chart, Stats & News
Cingulate Inc.
Save
27.08M
Market cap
–
Current P/E
–
Forward P/E
CING chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -148.94% |
ROE | -515.34% |
D/E | 3.50x |
Interest coverage ratio | 14.65x |
CING valuation
P/E | – |
P/S | – |
P/B | 13.83x |
P/CF | 0.00x |
P/FCF | 0.00x |
P/OCF | 0.00x |
PEG | -0.09x |
EV multiple | -1.96x |
About
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders.
Similar securities
Based on sector and market capitalization
Report issue